RxDoctor Payments Data

Matthew Sullivan, OD

Optometrist · Prescott, AZNPI 1053311472

Payments from drug & device makers

$826in general payments, 2019–2025

Across 33 payments — averaging $25.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bausch & Lomb Americas Inc.$338
  • AbbVie$164
  • Alcon$73
  • Aerie Pharmaceuticals, Inc.$63
  • Coopervision Inc.$56
  • Tarsus Pharmaceuticals, Inc.$48
  • plus $85 from 3 others

What the payments were for

  • Food & beverage$826100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$826 in reported general payments places this provider in the 50th percentile of 1,134 optometrist providers in Arizona.

See all optometrist providers in Arizona

Medicare billing

Part B allowed, 2024
$447,314
Medicare patients
1,320
Services billed
6,323

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost72$40,891
RocklatanNetarsudil Mesylat/Latanoprost23$22,145
Travoprost25$4,683
Latanoprost358$4,328
Brimonidine Tartrate48$3,318
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol12$2,488
Prednisolone Acetate37$2,307
Tobramycin-DexamethasoneTobramycin/Dexamethasone58$2,228
Difluprednate18$1,860
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat109$1,823
Ofloxacin62$595
Dorzolamide Hcl29$485
Timolol Maleate50$406
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha20$253
Cephalexin14$72

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan$164$40,89172 claims
Aerie Pharmaceuticals, Inc.Rocklatan$63$22,14523 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 1,134 optometrist providers in Arizona.

Other optometrist in Prescott

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →